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Upwardly mobile proteins
Workshop: The role of HMG proteins in chromatin structure, gene expression and neoplasia
Introduction
High Mobility Group proteins (HMGs) are a set of chromatin
proteins first identified in the 1970s because they are very abun-
dant and run fast on SDS–PAGE. In these and other properties
they resemble histones. And like histones, which have seen a
resurgence of interest thanks to the discovery that their modifica-
tion modulates transcription, HMGs are staging a comeback.
They now appear to be important and versatile players in the
same complex plot: they regulate the expression of genes in
normal or pathological conditions.
About a hundred researchers from four continents gathered for
2 days (May 1 and 2, 2000) at the Lister Hill Center of the NIH,
Bethesda, to discuss HMGs. Here we report on both the general
picture and some of the most novel results (at least to us). Only
work published in the last year is cited in the References; for
background information, excellent starting points are the
reviews by Bustin (1999) and Wegner (1999).
A rose is a rose is a rose
(but there are 2 × 3 HMGs)
HMGs were discovered by the British scientist H.M. Goodwin,
which has led some to speculate that their name reflects the
initials of the discoverer, or of Her Majesty’s Government.
Today, the name refers to two classes of proteins: the canonical
HMGs, and HMG-motif proteins. Canonical HMGs are ubiqui-
tous to eukaryotes but are absent in eubacteria and archaea.
They can be divided into three groups that are completely
dissimilar from one another at the level of sequence and
structure, but are internally homogeneous: the HMG1/2, HMG-
14/17, and HMG-I/Y families (Table I). Each family is character-
ized by a functional sequence motif: the HMG box, the nucleo-
some binding domain, or the AT-hook (Figure 1). HMG-motif
proteins contain one of these functional motifs, but the rest of the
sequence is different.
Some quantitative considerations are relevant here: an
‘average mammalian cell’ (3 × 109 bp genome) contains ∼106
molecules of HMG1/2, 105 of HMG-14/17 and 104 of HMG-I(Y),
whereas it would contain ∼2 × 107 core histone molecules.
HMG-motif proteins are much rarer, much more diverse (dozens
in a single organism) and can be cell-specific or stage-specific.
This taxonomy is unfortunate, however, for a single name
(HMG) refers to three very different motifs (or domains). Worse,
HMG-I and HMG1 belong to different families, but the
typographical mimetism of 1 (one) and I (capital i) keep
confusing the uninitiated. Michael Bustin and his two co-organ-
izers therefore proposed changing the nomenclature, using new
roots for each group (Table I):
• HMGB (HMG box) for the HMG1 family;
• ATHI (AT-hook) for the HMG-I(Y) family; and
• NSBP (nucleosome binding protein) for the HMG-14/17
family.
The new nomenclature did get some enthusiastic apprecia-
tion, but was also met with fears of discontinuity with the
previous literature, and warnings that man should not divide
what God united in a single gel. The issue should be discussed
further, but many felt that semantic barriers to the field should be
removed, and that the name HMG should be kept as a generic
indication for the three families. After all, one point that emerged
over and over at the meeting was that these proteins really do
have a common overarching property: they change the local
conformation of DNA and/or nucleosomes, and enhance their
accessibility and plasticity.
AT-hook proteins and the enhanceosome
paradigm
AT-hook proteins originally came into the limelight when
Thanos and Maniatis identified HMG-I(Y) as a critical compo-
nent in the formation of an ordered assembly of proteins over
enhancer DNA. Such structures, where protein–DNA and
protein–protein interactions synergize with each other, were
dubbed enhanceosomes.
HMG-I and HMG-Y are generated by alternative splicing of
the same gene, while the related protein HMGI-C is encoded by
a different gene. All of these proteins contain three AT-hooks.
This motif comprises a sequence of amino acids of the general
form Pro-Arg-Gly-Arg-Pro which, in the absence of DNA, has no
defined conformation. However, this sequence binds to the
minor groove of runs of A/T bases (see Figure 1A), adopting a
crescent-shaped conformation that is reminiscent of the minor-
groove binding drug netropsin. The occupancy of the minor
groove by a single AT-hook bends the DNA mildly towards the
major groove, whereas the binding of multiple AT-hooks can
induce complex structural alterations.
The archetypal enhanceosome is formed on the virus-
inducible enhancer of the human interferon-β gene (IFN-β),
which binds on overlapping sites the transcription factors ATF-2/
c-jun, IRF1/3/7, NF-κB and the protein HMG-I(Y). The IFN-β
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enhancer DNA is spontaneously curved towards the minor
groove, and this conformation is unfavourable for recognition by
its cognate transcription factors. HMG-I(Y) binds to multiple sites
within the enhancer via both intra- and intermolecular inter-
actions, reversing the curvature of the DNA towards the major
groove. NF-κB and ATF-2/c-jun now bind better, thanks to the
more favorable conformation of DNA. Multiple protein–protein
interactions among the transcription factors and the HMG-I(Y)
molecules then stabilize the enhanceosome, which then forms a
stable surface that in turn recruits the transcriptional coactivator
CBP/p300 as a complex with the pol II holoenzyme (Yie et al.,
1999).
D. Thanos (New York, NY) presented a full movie of the life
and works of the IFN-β enhanceosome, as determined by
immunoprecipitation of formaldehyde-fixed chromatin. The
IFN-β gene starts to be transcribed ∼6 h after infection, grows
into the most actively transcribed gene in the cell, and is turned
off within 24 h. Prior to activation, the enhancer is nucleosome-
free, but is surrounded by localized nucleosomes, one of which
abuts the TATA box. Two hours after infection, NF-κB binds to
its site, marking the formation of the enhanceosome. At 4 h,
GCN5 is present, and within 6 h it acetylates HMG-I(Y) on
Lys71, as shown by a specific anti-K71-HMG-I(Y) antibody.
HMG-I(Y) was already presumably associated to the enhanceo-
some, but K71 acetylation stabilizes the enhanceosome even
further. CBP, Pol II and BRG1 appear at 6–9 h. The human SWI–
SNF complex containing BRG1 in turn makes the chromatin
template more accessible. TFIID recruitment becomes apparent
at 9–12 h and is complete at 19 h. When HMG-I(Y) is eventually
acetylated by CBP on Lys65, this marks the disruption of the
enhanceosome, and by 24 h transcription, and enhancer occu-
pancy, decline. Critically, it is the acetylation of HMG-I(Y) that
appears to be the molecular switch that turns transcription on
and off.
Other genes are supposed to work like IFN-β, with the
assembly/disassembly of an enhanceosome controlling the
recruitment of the Pol II holoenzyme. However, so far there is a
dearth of bona fide enhanceosomes. R. Reeves (Pullman, WA)
reported that HMG-I(Y) remodels the chromatin at the promoter
of the human IL-2Rα gene following lymphocyte activation.
Fig. 1. Structure of AT-hooks and HMG boxes, as determined by the laboratory of M. Clore (Bethesda, MD). (A) The second AT-hook domain of the HMG-I(Y)
protein (purple) is bound to the minor groove of a synthetic DNA substrate (yellow); polar view down the long axis of the double helix. The side-chains of the
highly conserved arginine residues that form a planar crescent-shaped structure similar in shape to the drugs distamycin and netropsin are also depicted. (B) The
HMG box of human SRY (magenta) bound to the minor groove of the octanucleotide GCACAAAC. HMG boxes are composed of three α-helices and an extended
amino acid stretch at their N-terminus. The backbones of the HMG box domains of SRY, HMG1 and Drosophila HMG-D are almost exactly superimposable. The
DNA (yellow) is significantly distorted: the minor groove is widened considerably to accommodate the extended N-terminal stretch of the HMG box; the planes
of the bases are tilted; and the double helix is unwound and bent.
Table I. Nomenclature of HMG proteins
HMG family Member proteins DNA-binding domain New suggested names Superfamily of HMG-motif proteins
HMG1/2 HMG1, HMG2, HMG4 HMG box HMGB1, 2, 3 HMG-box proteins
HMG-I(Y) HMG-I, HMG-Y, HMGI-C AT-hook ATHI1(a,b), 2 AT-hook proteins
HMG-14/17 HMG-14, HMG-17 nucleosomal binding domain NSBP1, 2 nucleosome binding proteins
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HMG-I(Y) has the ability to bind to DNA packaged in nucleo-
somes (Reeves et al., 2000), and its multiple post-translational
modifications (phosphorylations and at least six different methyl-
ations, as well as acetylations) modulate this ability (Banks et al.,
2000). A large number of other genes require HMG-I(Y) for their
correct expression, but the details of the interactions on their
enhancers/promoters is less well known.
Fat, cancer and lipomas
A group of presentations focused on the role of HMG-I(Y) and
HMGI-C in normal and pathological adipocyte differentiation.
HMGI-C is predominantly expressed in proliferating, undifferen-
tiated mesenchymal cells and is absent in adult tissues.
However, the HMGI-C gene is rearranged, and expressed, in a
number of tumors of mesenchymal origin, including lipomas,
hamartomas and leiomyomata. The latter, popularly known as
uterine fibromas, are probably the most common tumors; they
affect between 20 and 70% of all females of reproductive age,
according to different estimates. In most rearrangements, breaks
occur within the large third intron of HMGI-C, resulting in a
protein that bears the three AT-hooks fused to a different
peptide.
K. Chada (Piscataway, NJ) gave an exciting report on the role
of HMGI-C in adipogenesis and obesity. Hmgi-c–/– mice (corre-
sponding to the classical pygmy mutants) are much smaller than
their siblings, with an almost 20-fold decrease in fat cells and a
reduction in mesenchymal tissues. The gene is always on in
preadipocytes, but in wild-type mice fed a normal diet expres-
sion is undetectable. On a high-fat diet, Hmgi-c expression
becomes significant because of an expansion of the preadi-
pocyte population. Disruption of Hmgi-c causes a striking
reduction in obesity of leptin-deficient mice (Lepob/Lepob), in a
dosage-dependent manner: Hmgi-c+/+ Lepob/Lepob weigh over
three times more than Hmgi-c–/– Lepob/Lepob animals, and
Hmgi-c+/– Lepob/Lepob are intermediate (Anand and Chada,
2000). HMGI-C therefore appears to be crucial in fat cell prolif-
eration, and is misexpressed in lipomas.
The question arises whether expression of Hmgi-c per se or
the fusion to other genes causes neoplastic transformation. A talk
by A. Fusco (Naples, Italy) and a poster by P. Arlotta (Cambridge,
MA) presented independent evidence that in transgenic mice the
truncated Hmgi-c gene is sufficient for adipocyte growth and
transformation (Battista et al., 1999; Arlotta et al., 2000).
Remarkably, only lipomas appear, although the gene is now
expressed in most tissues. The HMG-I(Y) protein can play a role
similar to HMGI-C in adipocyte differentiation: suppression of
HMG-I(Y) synthesis by antisense treatment blocks differentiation
of 3T3L1 preadipocytic cells. Moreover, HMG-I(Y) interacts
physically and functionally with C/EBP-β, a transcription factor
that controls the expression of fat-related genes such as the
leptin gene itself.
The HMG1 family
In contrast to the proteins of the HMGI-(Y) family, which are
expressed at low levels in differentiated tissues, HMG1 is present
in large amounts. Give or take some variation, there might be
one copy of HMG1 for every 2 kb of the human genome. HMG1
contains just two HMG boxes and an acidic tail of 30 aspartic
and glutamic acids. Moreover, its HMG boxes have no sequence
specificity on their own, and indeed bind very inefficiently to
standard, B-form DNA. However, HMG1 and its individual
boxes bind very well to DNA substrates that have a wide minor
groove: four-way junctions, severely undertwisted DNA, DNA
crosslinked by cisplatin drugs and DNA at the entry and exit sites
of nucleosomes. Conversely, when HMG1 binds to normal
B-form DNA, either because it is present in very high concentra-
tions or because it is recruited by interaction with other proteins,
it bends the double helix very significantly.
Why does HMG1 contain two boxes when in most in vitro
conditions just one will do? J. Thomas (Cambridge, UK) showed
that the two boxes are biochemically similar but not completely
equivalent, and R. Johnson (Los Angeles, CA) presented
evidence that two boxes, and not just one, are required for
enhanceosome formation by HMG1. The BHLF1 proximal
promoter in the Epstein–Barr virus is activated following the
binding of two dimers of the viral ZEBRA transcription factor to
closely spaced sites (Ellwood et al., 2000). HMG1 facilitates
their binding, and binds to DNA between them. HMG1 does not
bind to the promoter in the absence of ZEBRA, nor to ZEBRA in
the absence of the promoter. Moreover, ZEBRA requires the
architectural function of HMG1, as shown by the lack of tran-
scriptional activity of a promoter where the spatial arrangement
of the ZEBRA proteins has been altered by changing the helical
phase of their sites on DNA. Perhaps a recurrent theme here is
that architectural proteins are heavily involved in the fast
switching of gene expression (both on and off): in support of this,
yeast lacking its HMG1-related proteins NHP6A and -B is
severely retarded in the kinetics of activation of several induc-
ible genes. Nonetheless, these genes appear to attain some level
of transcription, and the double knockout of NHP6A and -B is
not lethal.
The cell’s appetite for HMG1 is surprising: transient over-
expression of HMG1 by transfection enhances the biological
activity of HMG1 interactors, be they HOX proteins, RAG1/2
recombinase, p53 or steroid hormone receptors. The effects are
not sensational (between 3- and 10-fold), but as someone
pointed out: if I were twice as tall, it would change my way of
life. Indeed, the transient 2-fold increase in the cellular content
of HMG1 that can be achieved by treating cells with proges-
terone or estrogen sensitizes the same cells to the cytotoxic
effects of cisplatin drugs (HMG1 bound to cisplatin adducts
inhibits nucleotide excision repair). S. Lippard (Cambridge, MA),
who reported the finding (He et al., 2000), is thus organizing a
clinical trial to investigate whether the antitumor efficacy of
cisplatin can be augmented by treating patients with steroid-
sensitive tumors with the appropriate steroid agonist.
Despite being apparently limiting in the cell, HMG1 is not
essential for cellular life. M.E. Bianchi (Milan, Italy) reported that
knockout mice for HMG1 are born, although they later die
because of problems with glucose metabolism just after birth, or
because of a large number of subtle defects if rescued from
hypoglycaemia with parenteral glucose administration
(Calogero et al., 1999). Cell lines containing no HMG1 can be
established and grow normally, although they are less respon-
sive to steroid hormones. HMG2 might provide partial redun-
dancy to HMG1, but HMG2 is expressed at significant levels
only during early embryogenesis, and in lymphoid tissues and
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testis in the adult. HMG2 knockouts only show a reduced
fertility in males, which correlates with increased apoptosis of
germ cells in seminiferous tubules and production of immobile
spermatozoa. Double knockouts for HMG1 and HMG2 are
being bred, and will be closely scrutinized for chromatin
organization, gene expression, and immunological defects
(which neither single knockout has). In vitro experiments clearly
show that either HMG1 or HMG2 is required for efficient V(D)J
recombination, possibly because HMG1/2 might render the
sequences recognized by the recombinase RAG1/2 accessible
even when packaged in nucleosomes (M. Oettinger, Cambridge,
MA).
D. Edwards (Denver, CO) showed that HMG1 (or HMG2)
greatly facilitates the binding of hormone receptors to DNA. The
effect is ∼10-fold on canonical palindromic receptor binding
sites, and in vitro HMG1 even makes possible the binding to
half-sites. This may be very relevant, since several hormone-
responsive genes do not contain recognizable receptor binding
sites. HMG1 exerts its effect on the zinc finger DNA-binding
domains of steroid receptors, but not on those of non-steroid
receptors (retinoic acids, thyroid hormones and vitamin D). The
difference appears to be rooted in the presence of an additional
α-helix C-terminal to the zinc fingers of non-steroid receptors,
that touches the minor groove almost on the opposite side of the
bases recognized in the major groove. When this C-terminal
extension (CTE) is grafted onto steroid receptors, they bind DNA
much better and become HMG1-insensitive. Conversely, non-
steroid receptors without the CTE bind DNA with reduced
affinity, and are HMG1-sensitive. Part of this effect might be
mediated via DNA conformation: the target sites get bent upon
binding of hormone receptors, and HMG1 might stabilize the
bending. The same may be true in other cases as well: p53,
RAG1 and TBP (another interactor of HMG1) all bend DNA to
varying extents.
HMG-box proteins and cell fate
determination
Sox (Sry-related HMG box) proteins are a growing family of
sequence-specific DNA binding proteins characterized by an
HMG domain highly related to that of Sry, the mammalian male
sex-determining factor. Sox proteins are present throughout the
animal kingdom and are involved in several major cell fate
determination processes. All Sox proteins are able to bind and
bend the same DNA sequences recognized by Sry. Protein–
protein interactions with other transcription factors play a
crucial role in selecting their in vivo target genes, enabling each
one to perform a specific function.
R. Lovell-Badge (London, UK) gave an exhaustive talk on the
role of Sox2. Sox2 is expressed both within the multipotent
precursor cells of the developing central nervous system, and in
the early mouse embryo. There, it controls the series of cell fate
decisions that restrict developmental potential in an asymmetric
fashion. The first decision is between making cells of the inner
cell mass (ICM) or the trophectoderm. The ICM cells then
develop into either the epiblast (giving rise to the embryo) or the
primitive endoderm (forming extraembryonic tissues). Each of
the early lineages depends on the others for its survival and
differentiation.
Gene inactivation experiments reveal that Sox2 is required in
at least two separate lineages. Sox2 protein is apparently laid
down in the oocyte cytoplasm and maternally inherited; all
blastocyst cells have Sox2 protein, but this is nuclear only in the
ICM. The protein is very stable, and can be detected in the
nucleus of +/+, +/– and –/– ICM cells. Sox2–/– embryos develop
normally up to blastocyst stage, but then ICM cells fail and only
fragments of extraembryonic tissue remain after implantation. If
Sox2+/+ ES cells are placed within –/– blastocysts, they rescue the
epiblast, and the embryo survives until Sox2–/– extraembryonic
ectoderm fails. Thus, Sox2 plays a crucial role both in the
embryo proper and in extraembryonic ectoderm. Apparently,
the combination of OCT4 and SOX2 is what determines the cell
fate; only Sox2 is present in extra-embryonic ectoderm, only
OCT4 in extra-embryonic endoderm, but the two proteins are
coexpressed in ICM.
Very little is known so far about the molecular targets of Sox
proteins, but M. Wegner (Erlangen, Germany), and V. Lefebvre
and B. de Crombrugghe (Austin, TX) found some.
Sox10 is expressed in the emerging neural crest, and later in
glial cells of the peripheral and central nervous systems. Inacti-
vation of one Sox10 allele causes dominant defects in multiple
neural crest-derived lineages, leading to Waardenburg–
Hirschsprung disease (characterized by combined deafness,
pigmentation defects and aganglionic megacolon) in humans,
and the similar Dom (dominant megacolon) phenotype in mice.
Also, loss of both Sox10 alleles in mouse is embryonic lethal and
wipes out melanocytes, the enteric nervous system and periph-
eral glia. ErbB3, which codes for a neuregulin receptor essential
for Schwann cell development, was identified as a Sox10 target
because its expression pattern in wild-type embryos parallels
that of Sox10, and Dom/Dom mice lose erbB3 expression in the
dorsal root ganglia. Protein zero (P0) is a major component of the
myelin sheaths of differentiated, axon-embracing Schwann cells.
Sox10 binds as a monomer or as a dimer to distinct sites within
the P0 promoter, in both cases activating gene expression
(Peirano et al., 2000).
L-Sox5, Sox6 and Sox9 code for master chondrogenic tran-
scription factors. The closely related L-Sox5 and Sox6 proteins
can dimerize and bind pairs of target sequences, but harbor no
transactivation domain and are thought to act as purely architec-
tural factors, whereas Sox9 can both bind DNA as a monomer
and transactivate genes, acting as a classical transcription factor.
The three proteins are expressed at high level at every site of
chondrogenesis in the mouse embryo, and cooperatively trans-
activate the Col2a1 collagen 2 gene. Knockouts demonstrate
that each of this trio of genes is essential for cartilage formation.
R. Grosschedl (Münich, Germany) was the first to demonstrate
an architectural activity for an eukaryotic transcription factor,
LEF-1. LEF-1 was initially identified as being lymphocyte-
specific, but is now known to control a vast number of differen-
tiation processes. In association with intranuclear β-catenin it
performs the last step in the WNT signaling pathway: turning on
the appropriate genes. In this mode, LEF-1 regulates inductive
interactions between epithelial and mesenchymal tissues, for
example in tooth formation: Wnt10 signals to the epithelial cells,
where LEF-1 in combination with β-catenin binds to a specific
enhancer of the Fgf4 gene. The LEF-1 knock-out has defective
tooth formation, which can however be rescued by the place-
ment of FGF4-releasing beads at the epithelial-mesenchymal
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junctions in organ cultures. LEF-1 also controls the expression of
the TCRα gene, but here the situation is completely different.
β-catenin is not involved, and just the HMG-box domain of
LEF-1 (without the β-catenin binding domain) is capable of
partially rescuing the thymus phenotypes of Lef-1 Tcf-1 double
knockouts. The architectural function of LEF-1 is all that is
needed, and actually the TCRα enhancer sequence can be
tweaked in such a way that the other transcription factors
comprising the putative enhanceosome can touch each other in
the correct way, even in the absence of LEF-1.
HMG-14 and -17 assist transcription
HMG-14 and -17 proteins wedge between the core histones and
the DNA gyrase in nucleosomes, or rather in ∼1% of them. This
average is however misleading: first, because two HMG-14 or
two HMG-17 molecules bind to the same nucleosome (mixed
HMG-14/HMG-17 binding to the same nucleosome is not
observed), and second, because runs of at least six nucleosomes
are associated to the same ‘flavor’ of HMG-14/17 (Y. Postnikov,
Bethesda, MD). This implies that HMG-14/17 alter both intra-
and inter-nucleosomal contacts, with an extensive cooperative
effect. HMG-14/17 ‘tagging’ of nucleosomes owes little to DNA
sequence, and depends on the transcriptional activity of the
DNA packaged into nucleosomes. R. Hock (Würzburg,
Germany) reported that in actively transcribing cells HMG-17 is
dispersed in a punctate pattern throughout the nucleus, but
relocalizes to interchromatin granule clusters (IGC) upon tran-
scription blockage with α-amanitin or actinomycin. Likewise,
HMG-14 colocalizes with BrUTP in in situ run-ons. Treatment of
cells with synthetic peptides corresponding to the nucleosome
binding domains of HMG-14/17 competes with binding by the
full-length proteins, and arrests transcription.
J. Herrera (Bethesda, MD) showed that the localization of
HMG-14/17 also responds to the progression of the cell cycle,
and depends on post-translational modifications (Bergel et al.,
2000). PCAF and p300 acetylate both proteins at several sites,
including the bipartite nuclear localization signal (NLS) and the
NBD. Moreover, both proteins can be multiply and differentially
phosphorylated. Phosphorylation is highest during M phase, and
causes the detachment of both proteins from nucleosomes. After
mitosis, HMG-14/17 must be dephosphorylated to re-enter the
nucleus. L. Mahadevan (Oxford, UK) presented evidence that
phosphorylation of HMG-14 may play a role in the expression of
immediate-early genes (Thomson et al., 1999).
Despite the non-equivalence of HMG-14 and HMG-17
binding to nucleosomes, a poster by Y. Birger (Bethesda, MD)
reported that Hmg-14–/– mice are alive and well. Embryonic
fibroblast lines established from the null mice grow significantly
faster than wild type controls, and reach higher saturation densi-
ties. Before concluding that HMG-14 is actually bad for your
cells, consider that the null fibroblasts are significantly more
sensitive to DNA damage. The rate of removal of thymidine
dimers, for example, is much reduced. The implication is that
HMG-14 may also be responsible for access to chromatin by
DNA repair machineries.
Conclusion
All three families of HMG play a role in chromatin that is
between the structural and the regulatory. Whereas HMG-14/17
modify nucleosomes directly, AT-hook and HMG-box proteins
remodel the regions of chromatin involved in gene control, and
organize enhanceosomes. The classical HMGs essentially
contain just the DNA binding domains, which double up as
domains for protein–protein interaction. In contrast, HMG-box
proteins may contain conventional activation domains, and the
same protein can act both as a classical transcription factor and
as an architectural component of chromatin, in a manner highly
dependent on cell type and promoter context. For sure, HMG-
motif proteins are both important and versatile, and their action
appears to be modulated by a plethora of post-translational
modifications. The meeting was deftly summed up by A. Wolffe
(Richmond, CA): there must be money in proteins that control
your fat, your teeth, your sex and your health (besides minor
things such as transcription, cell division, and DNA recombina-
tion and repair). All the participants came away with scientific
elation for an excellent meeting on Highly Motivating Great
proteins, and high hopes of personal wealth.
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